title: Better survival with statin administration after revascularization therapy in Japanese patients with coronary artery disease: perspectives from the CREDO-Kyoto registry.
abstract: BACKGROUND
  The importance of statins in cardiovascular prevention has been demonstrated in various patient subsets. This study aimed to evaluate the effects of statins on long-term outcomes of Japanese patients undergoing their first coronary revascularization.
  
  
  RESULTS
  A total of 9,225 patients undergoing their first coronary revascularizations during 2000--2002 were divided into 2 groups according to the use of statins at discharge; patients with acute myocardial infarction were not included. Statins was administered to only 28.5% (n=2,630) of the patients. The median follow-up period was 3.5 years. Patients on statin therapy showed lower all-cause (5.2% vs 10.0%; p<0.0001) and cardiovascular (3.2% vs 6.2%; p<0.0001) mortality than those without statins (n=6,595) by Kaplan-Meier analysis and log-rank test. After adjustment by multivariate analysis according to 29 variables, statin therapy remained as an independent predictor of reduced all-cause (relative risk ratio (RR) 0.71, 95% confidence interval (CI) 0.59-0.86, p=0.0005) and cardiovascular (RR 0.72, 95% CI 0.56-0.91, p=0.0067) mortality. The validity of RR of statin therapy in multivariate analysis was further confirmed by risk adjustment using propensity scores (all-cause mortality: propensity-adjusted RR 0.70, 95% CI 0.58-0.85, p=0.0003; cardiovascular mortality: propensity-adjusted RR 0.70, 95% CI 0.54-0.89, p=0.0038).
  
  
  CONCLUSIONS
  Statin therapy started at hospital discharge was associated with increased chance of survival in Japanese patients undergoing their first coronary revascularization.
authors.affiliation: Division of Cardiology, Kobe City Medical Center General Hospital, Kobe, Japan. furukawa@kcgh.gr.jp
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Furukawa
authors.forename: Ryoji
authors.initials: R
authors.lastname: Taniguchi
authors.forename: Natsuhiko
authors.initials: N
authors.lastname: Ehara
authors.forename: Neiko
authors.initials: N
authors.lastname: Ozasa
authors.forename: Yoshisumi
authors.initials: Y
authors.lastname: Haruna
authors.forename: Naritatsu
authors.initials: N
authors.lastname: Saito
authors.forename: Takahiro
authors.initials: T
authors.lastname: Doi
authors.forename: Kozo
authors.initials: K
authors.lastname: Hoshino
authors.forename: Satoshi
authors.initials: S
authors.lastname: Shizuta
authors.forename: Takeshi
authors.initials: T
authors.lastname: Morimoto
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Imai
authors.forename: Satoshi
authors.initials: S
authors.lastname: Teramukai
authors.forename: Masanori
authors.initials: M
authors.lastname: Fukushima
authors.forename: Toru
authors.initials: T
authors.lastname: Kita
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kimura
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000401:mortality*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D001026:Coronary Artery Bypass / Q000009:adverse effects / Q000401:mortality*; D003324:Coronary Artery Disease / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007564:Japan; D053208:Kaplan-Meier Estimate; D008297:Male; D015999:Multivariate Analysis; D010351:Patient Discharge; D016016:Proportional Hazards Models; D012042:Registries; D012189:Retrospective Studies; D018570:Risk Assessment; D055502:Secondary Prevention; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors